ArticlePLoS biology2013
Reflections on the cost of "low-cost" whole genome sequencing: framing the health policy debate.
Article in PLoS biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial.Genetics in medicine : official journal of the American College of Medical Genetics · 2018Trial
- Whole exome sequencing in molecular diagnostics of cancer decreases over time: evidence from a cost analysis in the French setting.The European journal of health economics : HEPAC : health economics in prevention and care · 2021Article
- A scoping review of social and behavioral science research to translate genomic discoveries into population health impact.Translational behavioral medicine · 2021Article
- Genomics reveals the novel species placement of industrial contaminant isolates incorrectly identified asMicrobial genomics · 2021Article
- Utility of Genetic Testing from the Perspective of Parents/Caregivers: A Scoping Review.Children (Basel, Switzerland) · 2021Article
- Genomic Testing for Relapsed and Refractory Lymphoid Cancers: Understanding Patient Values.The patient · 2021Article
- SNP and Haplotype Regional Heritability Mapping (SNHap-RHM): Joint Mapping of Common and Rare Variation Affecting Complex Traits.Frontiers in genetics · 2021Review
- Precision Population Medicine in Primary Care: The Sanford Chip Experience.Frontiers in genetics · 2021Article
- Genome Diagnostics: Novel Strategies for Measuring Value.Journal of managed care & specialty pharmacy · 2019Article
- Cooperation between non-essential DNA polymerases contributes to genome stability in Saccharomyces cerevisiae.DNA repair · 2019Article
- Evaluating the Integration of Genomics into Cancer Screening Programmes: Challenges and Opportunities.Current genetic medicine reports · 2019Review
- Cost Analyses of Genomic Sequencing: Lessons Learned from the MedSeq Project.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2018Article
- Care and cost consequences of pediatric whole genome sequencing compared to chromosome microarray.European journal of human genetics : EJHG · 2017Article
- A microcosting and cost-consequence analysis of clinical genomic testing strategies in autism spectrum disorder.Genetics in medicine : official journal of the American College of Medical Genetics · 2017Article
- Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers.British journal of cancer · 2017Article
- Finding the right balance between precision medicine and personalized care.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2017Review
- The cost and cost trajectory of whole-genome analysis guiding treatment of patients with advanced cancers.Molecular genetics & genomic medicine · 2017Article
- Mechanisms and consequences of aneuploidy and chromosome instability in the aging brain.Mechanisms of ageing and development · 2017Review
- A time-and-motion approach to micro-costing of high-throughput genomic assays.Current oncology (Toronto, Ont.) · 2016Article
- Attitudes to incorporating genomic risk assessments into population screening programs: the importance of purpose, context and deliberation.BMC medical genomics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
Abstract
The cost of whole genome sequencing is dropping rapidly. There has been a great deal of enthusiasm about the potential for this technological advance to transform clinical care. Given the interest and significant investment in genomics, this seems an ideal time to consider what the evidence tells us about potential benefits and harms, particularly in the context of health care policy. The scale and pace of adoption of this powerful new technology should be driven by clinical need, clinical evidence, and a commitment to put patients at the centre of health care policy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.